NCT06230328Completed
Brazilian Reality of Hepatocellular Carcinoma
Brazilian Reality of Hepatocellular Carcinoma - BRA-HEP: Multicenter Retrospective Study (Real World Evidence - RWE)
Source: ClinicalTrials.gov · Last updated 29 Sept 2025
Brief summary (registry, in English)
National, multicenter, retrospective, non-randomized observational study (Real World Evidence-RWE) with the purpose of analyzing the epidemiological profile of Hepatocellular Carcinomas (BCLC A, B or C), clinical management, progression profile and overall survival of castrated patients treated in national oncology care reference centers, within the last 6 years (between 2017 to 2022).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 300 (actual)
- First submitted
- 22 Dec 2023
- Start date
- 15 Apr 2024
- Primary completion date
- 14 Nov 2024
- Lead sponsor
- AstraZeneca
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06230328
What you commit to
- Study type: Observational
- Participants enrolled: 300
- From 15 Apr 2024 to the primary completion date, 14 Nov 2024
- 11 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with only 1 visit to the participating site healthcare service, with loss to follow-up prior to the second visit to the participating site healthcare service;
- Previous treatment for hepatocellular carcinoma in another institution;
- Treatment with investigational drugs in a clinical trial.
Other
- Fibrollamelar carcinoma, hepatoblastoma, intrahepatic cholangiocarcinoma, neuroendocrine tumors or other less common types of liver tumors;
- Patients with incomplete staging data;
Who the study is looking for
- Male and female;
- Above 18 years old;
- Hepatocellular carcinoma diagnosis (confirmed by biopsy or imaging);
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (11)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Barretos | Brazil | Unknown status |
| - Coordinator of this site? Confirm its status | Belo Horizonte | Brazil | Unknown status |
| - Coordinator of this site? Confirm its status | Curitiba | Brazil | Unknown status |
| - Coordinator of this site? Confirm its status | Natal | Brazil | Unknown status |
| - Coordinator of this site? Confirm its status | Porto Alegre | Brazil | Unknown status |
| - Coordinator of this site? Confirm its status | Recife | Brazil | Unknown status |
| - Coordinator of this site? Confirm its status | Rio de Janeiro | Brazil | Unknown status |
| - Coordinator of this site? Confirm its status | Salvador | Brazil | Unknown status |
| - Coordinator of this site? Confirm its status | São Bernardo do Campo | Brazil | Unknown status |
| - Coordinator of this site? Confirm its status | São Paulo | Brazil | Unknown status |
| - Coordinator of this site? Confirm its status | Vitória | Brazil | Unknown status |
Related publications
- Real-World Epidemiology, Treatment Patterns, and Outcomes of Hepatocellular Carcinoma in Brazil: A Multicenter Retrospective Study.JCO Glob Oncol · 2026 · PMID 42341247
This page is information, not medical advice. Discuss any trial with your doctor.